In today’s fast-evolving biopharmaceutical landscape, manufacturers demand upstream solutions that combine high productivity, scalability, and batch-to-batch consistency without sacrificing quality. Lonza’s TheraPRO® CHO Media System is a chemically defined, non-animal origin (NAO) platform optimized to enhance protein expression in CHO-K1 and CHO-GS cell lines. Engineered for ease of use and process flexibility, TheraPRO® delivers superior viable cell densities and protein titers compared to leading commercial media, while ensuring seamless scale-up from research to commercial manufacturing. This session will demonstrate how TheraPRO® can streamline workflows, improve reproducibility, and shorten development timelines, supported by recent performance data. As the demand for faster, more reliable protein production intensifies, TheraPRO® enables process developers to move confidently from early-stage development to commercial success.

Speaker:

Kelly Molder
Head of Technical Excellence EMEA, Global Media Solutions
Lonza

Manufacturing cell and gene therapies (CGTs) is complex and expensive, often resulting in insufficient yields to satisfy commercial demand and high costs that may limit patient access. With an anticipated rise in demand for CGTs in the coming years due to ongoing successful development for new and broader therapeutic applications, it is increasingly crucial to explore novel technologies for creating more accessible and affordable therapeutics.

In this webinar, Virica’s experts will introduce a comprehensive solution that addresses the most pressing challenges in cell and gene therapy manufacturing. We’ll showcase how our Viral Sensitizers (VSETM) serve as a simple additive that dramatically enhances upstream productivity—without adversely impacting your process—while our integrated suite of services takes optimization to the next level. Drawing on decades of expertise in Design of Experiments (DoE), High Throughput Virology (HTVTM), and analytical services, Virica will demonstrate how we collaborate with partners to rapidly develop and implement application-specific VSE libraries. Discover how our combined product and service offerings can significantly increase yields, shorten timelines, and lower costs, all in one comprehensive approach tailored to your needs.

• Discover how Virica leverages High Throughput Virology (HTVTM) and Design of Experiments (DoE) to rapidly optimize upstream production. Our approach enables simultaneous testing of 360 unique conditions and 1080 runs in one week.
• Explore the latest case studies on our curated library of purpose-built VSEs across a range of applications delivering up to a 7x increase in productivity without disrupting your process.
• Discover an accessible approach to reducing high manufacturing costs and unlocking significant long-term savings

Speakers:

Jondavid de Jong
Vice President of Scientific Operations
Virica Biotech

Stabilising therapeutic proteins against aggregation remains challenging, whether through formulation or mutation. Characterisation of the mechanisms of aggregation has led to deeper understanding and can partially inform formulation and mutational strategies. This presentation will examine the impacts of mutations, pH, ionic strength, buffer and excipient interactions, temperature, and protein concentration, on the kinetics of aggregation for an antibody fragment. Biophysical analyses and molecular dynamics simulations for these conditions reveal how the resulting formulations or mutations affect aggregation kinetics. In parallel, the use of explainable machine learning approaches provide predictive tools, but also shed more light on the mechanisms through which formulations and mutations work.

Speaker:

Paul Dalby
Professor of Biochemical Engineering and Biotechnology
UCL

An efficient scale-up strategy is crucial for translating R&D successes into commercially viable bioprocesses. Constant bioreactor properties over different scales as well as fitting scale-up parameters not only ensure consistent product quality and yields, but also minimize time- and resource-consuming troubleshooting when moving from the experimental small scale towards commercial manufacturing. However, developing the right scale-up strategy can be a time-consuming process in itself. Join us for this webinar and learn about bioprocess transition in 3 L to 250 L single-use bioreactors, the selection of scale-up parameters, and the possibility to automate the scale-up by the Eppendorf Scale Up Assist feature. The webinar will offer valuable insights on reducing development time and optimizing bioreactor operations for both academic and industrial applications.

Speaker:

Alwin Albers
Global Marketing Manager Bioprocess
Eppendorf SE

Adeno Associated Virus (AAV) vectors are the leading platform for gene delivery for the treatment of a variety of human diseases. During development, AAV in-process samples often yield mixed populations of particles that include full capsids, partially full capsids and empty capsids amongst others. This heterogeneity during production necessitates that product characterization be efficiently done to establish the empty to full capsid ratios. Empty-to-full ratios capsids can range from 20% to over 98% in vector preparations when produced by standard transient transfection production pipelines leading to a great need for suitable analytical characterization methods. While there are many techniques that have been deployed to detect these ratios, they are often either expensive or time consuming in addition to many other challenges hence making it difficult for developers to identify an ideal cost-effective technique. Sartorius’s AAVX biosensor was developed to enable rapid, real time and high-throughput measurement of AAV capsid titer in samples across the AAV bioprocess workflow enabling quick process optimization, quality checks and increased productivity. In this talk, we propose a method that extends the use of the AAVX biosensors for use in determining empty to full capsid ratios; a method that does not require the lengthy and often inefficient capsid lysis to expose the ssDNA targeted for binding and subsequent detection by some comparative methods.

Speaker:

David O. Apiyo, PhD
Manager of BioAnalytics Applications Development
Sartorius

Session Description Coming Soon!

Speaker:

Jie Chen
Director, API Pilot Plant
Abbvie

We present a novel modular pilot-scale benchtop cGMP hygienic system that can run major downstream purification processes such as chromatography, tangential flow filtration (TFF), SSTFF/SPTFF, normal flow filtration (NFF), inline dilution (ID), and various process intensifications such as 4C continuous chromatography and integrated processes (ie. Connected Batches). This platform serves as a one-stop shop for tech transfer and features its powerful functionality for configuring intensified processes and connected batches with three key innovative process configurations as well as a comprehensive industrial DCS control and data management framework. The key configurations enabled the possibility of connecting as many as 6 individual chromatography or TFF/NFF batches without using surge tanks in between. The system represents a transformative shift in how to develop biopharmaceutical downstream processing and can play a critical POC role for tech transfer especially when it comes to process intensification (PI).

Speaker:

Zuwei Jin, PhD
VP, Global Business Development
Lisure Technology Co.

In this presentation, CPC’s Maria Bollensen will review the benefits of modular systems used in manufacturing biologics and how you can ensure that your process remains closed. Both modular and single-use systems present the means to reduce costs, increase productivity, improve quality, reduce risk, and increase flexibility in biopharmaceutical applications.

Attendees will also gain insight into:

• The core principles of modular system design within bioprocess manufacturing and how sterile connectors enable it.
• The benefits of incorporating a modular system design using sterile connectors and how this approach helps minimize risk for your process.
• Testing within the manufacturing process to ensure the best outcomes.
• Addressing BPOG’s extractable protocol and how it relates to the USP 665 regulation going into effect in 2026.

Speaker:

Maria Bollensen
Product Manager
CPC

Digital Transformation is a big buzz word. However, do we really need to enroll on it now? There is the risk that a large transformation program costs a lot of money and the benefits are scarce.

What are the benefits? What would happen if I wait a bit?. If we start, how to start?

This contribution formulates multiple theses for the integration of digitalization in the process industry and demonstrates that the organization would not survive increase if we don’t follow this path.

As a solution, we emphasize the individual steps to take to yield low hanging fruits along the product life cycle and show a structured workflow to engage your organization.

Speaker:

Christoph Herwig
Senior Scientific Advisor Körber Pharma Austria
Vienna